-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2024-518405-18-00
6
2018-12-07
Depressive disorder
-
2023-509061-20-00
9
2018-11-22
Advanced solid tumors
-
2023-507312-13-00
5
2018-11-15
Multiple Myeloma
-
2024-514179-17-00
5
2018-10-02
Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
-
2023-504038-23-00
9
2018-05-10
Metastatic non-small cell lung cancer (NSCLC)
-
2024-515356-21-00
5
2018-04-17
Adult subject (18 years of age older) with low or intermediate-1 IPSS
-
2022-500251-22-00
4
2018-04-12
This study will include all patients having received at least one infu
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
-
2023-510200-42-00
5
2017-12-06
primary sclerosing cholangitis (PSC)
-
2023-509595-42-00
5
2017-10-31
Gastric and gastroesophageal junction (GEJ) adenocarcinoma
-
2022-501251-81-00
5
2017-06-08
Renal cell carcinoma
-
2023-506739-14-00
4
2017-05-12
Spinal Muscular Atrophy (SMA)
-
2022-501360-18-00
5
2017-03-15
Early Stage Non-Small Cell Lung Cancer (NSCLC)
-
2024-511967-26-00
5
2016-11-21
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
-
2023-507294-18-00
5
2016-09-16
Metastatic renal cell carcinoma
-
2023-509360-24-00
5
2016-06-16
Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
-
2022-502526-41-00
4
2016-03-15
Non-Muscle Invasive Bladder Cancer (NMIBC)
-
2023-509352-34-00
4
2015-06-18
Mantle Cell Lymphoma
-
2023-508067-70-00
9
2015-04-15
Neoplasms by site
-
2024-518931-12-00
4
2014-05-15
Neuroblastoma
-
2023-509472-42-00
5
Relapsed and/or
Refractory Multiple Myeloma
-
2023-510289-28-00
4
Sickle Cell Disease (SCD) and Nephropathy
-
2023-510340-20-00
3
Systemic Lupus Erythematosus